Ionis Pharmaceuticals Completes Enrollment In Pivotal Cohort (Cohort 1) Of REVEAL Phase 3 Reveal Study Of Obudanersen (ION582) Angelman Syndrome; Adult Cohort (Cohort 2) Is Expected To Complete Enrollment In Q3 2026; Topline Data Expected In 2H 2027

Loading news article.

Ionis Pharmaceuticals Completes Enrollment In Pivotal Cohort (Cohort 1) Of REVEAL Phase 3 Reveal Study Of Obudanersen (ION582) Angelman Syndrome; Adult Cohort (Cohort 2) Is Expected To Complete Enrollment In Q3 2026; Topline Data Expected In 2H 2027 | WAPE

Ionis Pharmaceuticals Completes Enrollment In Pivotal Cohort (Cohort 1) Of REVEAL Phase 3 Reveal Study Of Obudanersen (ION582) Angelman Syndrome; Adult Cohort (Cohort 2) Is Expected To Complete Enrollment In Q3 2026; Topline Data Expected In 2H 2027

Article summary

Related companies

Comments —